Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic
  • Search Hotels in Pleasanton

  • ROOMS:

Lupus Nephritis Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – Novartis, RemeGen, Roche, Annexon, Argenx, AstraZeneca, Aurinia

Lupus Nephritis Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies - Novartis, RemeGen, Roche, Annexon, Argenx, AstraZeneca, Aurinia
Delveinsight Business Research LLP
The Lupus Nephritis market size was USD 1,577.8 million in 2021, which is expected to rise during the study period (2019–2032). As per DelveInsight, the Lupus Nephritis Market is anticipated to evolve immensely in the coming years owing to the rising prevalent population of Lupus Nephritis in the 7MM and the launch of novel therapies in the market.

DelveInsight's "Lupus Nephritis Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Lupus Nephritis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Lupus Nephritis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Lupus Nephritis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Lupus Nephritis Market

Lupus Nephritis: An Overview

As per the National Kidney Foundation (NKF), there are two types of lupus. Systemic lupus erythematosus (SLE) is a form of lupus that can harm the skin, joints, kidneys, and brain and can be fatal. The other form of lupus is called "discoid" lupus erythematosus, which affects only the skin. When Systemic lupus erythematosus affects the kidneys, it is called lupus nephritis (LN).

Systemic lupus erythematosus is a prototypic autoimmune disease and is the most common form of lupus that can affect multiple tissues and organs. The disease is characterized by the production of antibodies to components of the cell nucleus in association with a diverse array of clinical manifestations.

Lupus Nephritis is a common and potentially devastating manifestation of Systemic lupus erythematosus. It is a leading cause of morbidity and mortality in patients with Systemic lupus erythematosus. Lupus nephritis leads to inflammation of small blood vessels, which play an important role in filtering waste materials in the kidney. It also involves the inflammation of glomeruli. Common signs of Lupus Nephritis are hematuria, proteinuria, edema, and sudden weight gain.

Lupus Nephritis Market Key Facts

  • In the year 2021, the total number of diagnosed cases of Lupus Nephritis was 209,166 cases in the 7MM.

  • The total Lupus Nephritis market size in the United States accounted for USD 975.1 million in 2021.

  • In EU5, the total Lupus Nephritis market size was USD 392 million in 2021.

  • In Japan, the total Lupus Nephritis market size was USD 211.1 million in 2021.

Lupus Nephritis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Lupus Nephritis pipeline therapies. It also thoroughly assesses the Lupus Nephritis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Lupus Nephritis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Lupus Nephritis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Lupus Nephritis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Lupus Nephritis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Lupus Nephritis Epidemiology, Segmented as -

  • Total Prevalent Cases of Systemic Lupus Erythematosus in the 7MM [2019–2032]

  • Total Diagnosed Prevalent cases of Lupus Nephritis in the 7MM [2019–2032]

  • Gender-Specific Cases of Lupus Nephritis in the 7MM [2019–2032] 

  • Class-Specific Cases of Lupus Nephritis in the 7MM [2019–2032]

  • Treated Cases of Lupus Nephritis in the 7MM [2019–2032]

Lupus Nephritis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Lupus Nephritis market or expected to be launched during the study period. The analysis covers the Lupus Nephritis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Lupus Nephritis drugs based on their sale and market share.

The report also covers the Lupus Nephritis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Lupus Nephritis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Lupus Nephritis Market Will Evolve and Grow by 2032 @

Lupus Nephritis Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Lupus Nephritis. Currently, Roche is leading the therapeutics market with its Lupus Nephritis drug candidates in the most advanced stage of clinical development.

Lupus Nephritis Companies Actively Working in the Therapeutics Market Include

  • Annexon

  • Argenx

  • AstraZeneca

  • Aurinia Pharmaceuticals

  • Boehringer Ingelheim

  • Equillium

  • Horizon Therapeutics

  • Novartis

  • RemeGen

  • Roche

And Many Others

Emerging and Marketed Lupus Nephritis Therapies Covered in the Report Include:

  • GAZYVA/ GAZYVARO (obinutuzumab): Roche

  • Daxdilimab: Horizon Therapeutics

  • Itolizumab: Equillium

  • SAPHNELO (anifrolumab): AstraZeneca

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Lupus Nephritis Competitive Intelligence Analysis

4. Lupus Nephritis Market Overview at a Glance

5. Lupus Nephritis Disease Background and Overview

6. Lupus Nephritis Patient Journey

7. Lupus Nephritis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Lupus Nephritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Lupus Nephritis Unmet Needs

10. Key Endpoints of Lupus Nephritis Treatment

11. Lupus Nephritis Marketed Therapies

12. Lupus Nephritis Emerging Drugs and Latest Therapeutic Advances

13. Lupus Nephritis Seven Major Market Analysis

14. Attribute Analysis

15. Lupus Nephritis Market Outlook (In US, EU5, and Japan)

16. Lupus Nephritis Companies Active in the Market

17. Lupus Nephritis Access and Reimbursement Overview

18. KOL Views on the Lupus Nephritis Market

19. Lupus Nephritis Market Drivers

20. Lupus Nephritis Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Photography by Christophe Tomatis
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.